Dr. Carl June, The Father Of CAR-T Immunotherapy:  A New Last Chance For Cancer Patients

Dr. Carl H. June, MD, of the University of Pennsylvania, who is one of the pioneers of CAR-T cell therapy, will share all about his CAR T-Cell Journey and the Cancer Treatment Revolution with CureTalks on November 15, 2017, 1 PM EST.


#ASH17: The big loser in CAR-T, Juno is making a bid to seize the fast lane to frontrunner status – ENDPOINTS NEWS

Juno Therapeutics may have lost the initial race for FDA approval of CAR-T (to Novartis and Gilead [Kite]), but they are preparing to demonstrate at December’s ASH 17 conference (American Society of Hematology), that theirs is the superior CAR-T therapy:

The analogy I’ll give you,” says R&D chief Sunil Agarwal: “Small changes in the antibody world can make big differences; all CARs are not the same… I think these data continue to support a best-in-class profile.”


(FYI, The CAR-T therapy I underwent at MSK in 2015 was in partnership with Juno, although the protocol was not JCAR017)

Novartis asks FDA to expand Kymriah’s use against blood cancer

The logical next step in the evolution of CAR-T has occurred. Novartis’ Kymriah has already been approved for leukemia, while Gilead’s (originally Kite’s) Yescarta has been approved for diffuse large B-cell lymphoma (DLBCL). Now Novartis has filed for approval of Kymriah for DLBCL as well:


Request for Feedback: What would you like to find on this blog?

Dear Readers,

Thanks to references from Lympho Bob and the Facebook group CAR T-CELL Patients And Carers, this blog has recently received upwards of 20 visits per day.  However, we’ve noticed that most visitors are finding little content to actually “click through”.  Perhaps the coverage here is not relevant to the typical reader?

So we ask you to please do us a small favor… Just take a moment to leave a comment here detailing what brought you here, what you were hoping to find, and what you think should be here on this blog.  We certainly don’t want to waste anyone’s time with information they deem irrelevant or uninteresting, and we want this blog to be a useful resource for readers.  Your feedback would be most appreciated!

— Ben & Bill

CAR-T free webinar Oct. 3, a new CAR-T entrant, etc…

CAR-Therapy: A New Twist on Transplants (free webinar Oct. 3 from the Blood & Marrow Transplant Information Network)

A long article (you must navigate across several pages) that covers the topic well…

CAR T-cell therapy approval huge step for oncology, but only ‘beginning of story’

CAR-T Cell Therapy Is Here To Stay

Autolus, a British startup that has made news for raising $$ for their new CAR-T trials in lymphoma and multiple myeloma:

UK start-up Autolus starts ‘living medicine’ cancer trials

Three CAR-T cell therapy studies announced from UK start-up Autolus – EPM Magazine

British biotech joins race to find ‘living medicines’ for cancer after cash injection

‘Living medicine’ cancer therapy starts clinical trials – GOV.UK

Autologous CAR-T Cell Manufacturing: Current Standing and Future Directions | GEN

Unpacking what $475,000 means (Slide presentation from Memorial Sloan-Kettering that turned up in social media)

(7) CAR-T – Welcome to the Jungle! | LinkedIn

Why Fred Hutch’s chief is enlisting techies to defeat cancer by 2025 – GeekWire